v3.26.3
Fair value measurement (Tables)
 9 Months Ended
Sep. 30, 2026
Fair Value Disclosures [Abstract]  
Summary of Financial Items Carried at Fair Value
Financial items carried at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 are classified in the tables below in one of the three categories of fair value levels:
September 30, 2026
Level 1 Level 2 Level 3 Total
(U.S. $ in millions)
Cash and cash equivalents:
Money markets$3,003 $— $— $3,003 
Cash, deposits and other1,082 — — 1,082 
Investment in securities:
Equity securities15 — — 15 
Other3 — — 3 
Derivatives:
Asset derivatives:
     Options and forward contracts— 52 — 52 
Liability derivatives:
     Options and forward contracts— (56)— (56)
     Cross currency interest rate swap— (14)— (14)
Contingent consideration*— — (43)(43)
Total$4,103 $(18)$(43)$4,042 
December 31, 2025
Level 1Level 2Level 3Total
(U.S. $ in millions)
Cash and cash equivalents:
Money markets$2,678 $— $— $2,678 
Cash, deposits and other878 — — 878 
Investment in securities:
Equity securities16 — — 16 
Other3 — — 3 
Derivatives:
Asset derivatives:
     Options and forward contracts— 86 — 86 
Liability derivatives:
     Options and forward contracts— (38)— (38)
     Cross currency interest rate swap— (19)— (19)
Contingent consideration*— — (51)(51)
Total$3,575 $29 $(51)$3,553 
__________
*    Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs
The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs:
Nine months ended September 30, 2026Nine months ended September 30, 2025
(U.S. $ in millions)
Fair value at the beginning of the period$(51)$(401)
Adjustments to provisions for contingent consideration:
     Allergan transaction— (25)
      Eagle transaction(20)(20)
      Novetide transaction(2)(1)
Settlement of contingent consideration:
      Allergan transaction— 212 
      Eagle transaction28 35 
      Novetide transaction2 2 
Fair value at the end of the period$(43)$(198)
Summary of Financial Instrument Measured on a Basis Other Than Fair Value
Financial instruments measured on a basis other than fair value mostly consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs):
Estimated fair value*
September 30,December 31,
20262025
(U.S. $ in millions)
Senior notes and sustainability-linked senior notes included under senior notes and loans$12,152 $15,128 
Senior notes and convertible senior debentures included under short-term debt4,033 1,801 
Total$16,185 $16,929 
__________
* The fair value was estimated based on quoted market prices.